Figure 3

Expression levels of miR-122 and its targets in vitro and in vivo. The Roux-en-Y gastric bypass results in the altered miR-122 expression levels in plasma (a) and the liver (b) measured by quantitative PCR. (c) The expression levels of miR-122 mRNA targets, including citrate synthase (Cs), glucose transporter protein type 1 (Glut1), glucose-6-phosphate dehydrogenase (G6pd), fatty-acid synthase (Fasn), AMP-activated kinase beta 1 (Prkab1), uncoupling protein 2 (Ucp2), glucose-6-phosphatase (G6pc) and aldolase A (Aldoa), are measured by quantitative PCR in the liver of RYGB- (n=8) and SHAM- (n=5) operated animals. (d) These targets were evaluated in B13H cells transfected with miR-122 mimic (treatment, n=4) or scrambled miRNA (control, n=4) and measured by quantitative PCR. (e) A previous in vivo study by Elamn et al (Data were extracted from Array Express Experiment No. E-MEXP-1406, n=5 each group). (f) Immunoblot of the hepatic protein expression levels of citrate synthase, UCP2, AMPK-beta 1 and phosporylated AMPK-beta 1 in the RYGB- and sham-operated animals. (g–j) show quantified protein expressions of citrate synthase, UCP2, AMPK-beta 1 and phospho-AMPK-beta 1, respectively. All data represent mean±s.e.m. (RYGB, n=8; SHAM, n=5), unless otherwise specified in each figure. *P<0.05; **P<0.01; ***P<0.001.